United States Patent m
Fritzberg et al.
[54] METAL RADIONUCLIDE LABELED
PROTEINS FOR DIAGNOSIS AND THERAPY
[75] Inventors: Alan R. Fritzberg, Edmonds;
Sudhakar Kasina, Kirkland; Linda M.
Gustavson, Seattle, all of Wash.
[73] Assignee: NeoRx Corporation, Seattle, Wash.
[21] Appl. No.: 90,609
[22] Filed: Jul. 12, 1993
Related U.S. Application Data
[60] Continuation-in-part of Ser. No. 576,343, Aug. 31, 1991, Pat. No. 5,242,679, which is a division of Ser. No. 65,017, Jun. 19, 1987, Pat. No. 5,175,343, which is a continuationin-part of Ser. No. 817,321, Jan. 9, 1986, abandoned, which is a continuation-in-part of Ser. No. 692,000, Jan. 14, 1985, abandoned.
[51] Int. CI.6 C07D 235/02; C07C 69/62;
C07C 229/14; A61K 49/00; A61K 43/00
[52] U.S. CI 548/303.7; 530/391.5;
530/402; 534/10; 534/14
[58] Field of Search 548/304.1, 303.7;
530/391.5, 402; 560/145; 534/10, 14; 424/1.1,
9
[56] References Cited
U.S. PATENT DOCUMENTS
4,233,284 11/1980 Fawzi 424/1
4,421,735 12/1983 Haberetal 424/1.1
4,444,690 4/1984 Fritzberg 424/1
4,671,958 6/1987 Rodwell et al 424/85
4,673,562 6/1987 Davison et al 424/1
4,775,745 12/1986 Ford et al 424/1
4,833,251 11/1987 Musso et al 424/1
4,861,869 8/1989 Nicolotti et al 530/402
4,863,713 9/1989 Goodwin et al 424/1.1
4,895,955 1/1990 Ford et al 548/303
4,898,951 2/1990 Symons 548/303
4,963,682 10/1990 Bodor 546/338
4,963,688 10/1990 Bodor 546/316
5,242,679 9/1993 Fritzberg et al 424/1.1
5,283 342 2/1994 Gutavson et al 548/304.1
OTHER PUBLICATIONS
Davison et al., Inorganic Chem., vol. 20, No. 6, Jun. 1981, "A new class of oxotechnetium (5+) chelate complexes containing a TcON2S2 core".
Fritzberg, J. Nucl. Med. Tech., vol. 12, No. 4, Dec. 1984, pp. 177-188, "Current status of renal radiopharmaceuticals". Fritzberg et al., Amer. Chem. Soc. Abstracts, Abstract No. 70, (1984), "Labeling of proteins by chelate conjugation with Tc-99m and Re-188".
Kasina et al., J. Nucl. Med., vol. 29, pp. 1933-40, (1986) "Tissue distribution properties of technetium-99m-diamide dimercaptide complexes and potential use as renal radiopharmaceuticals".
Kasina et al., Sixth International Symp. on Radiopharmaceutical Chem., Boston, Jul. 1986, paper 118 "Application of diamide dimercaptide N2S2 bifunctional chelating agents for 99mTc-labeling of proteins".
ii'iriiiiiii ...
US005556982A [li] Patent Number: 5,556,982 [45] Date of Patent: Sep. 17, 1996
Fritzberg, Nuklearmedizin, vol. 26, pp. 7-12, 1987,
"Advances in 99Tc-labeling of antibodies".
Fritzberg et al., J. Nucl. Med., vol. 23, pp. 592-598, 1982,
"Synthesis and biological evaluation of Tc-99m N,N-Bis
(mercaptoacetyl)-2,3-diaminopropanoate: A potential
replacement for [131I]o-iodohippurate".
Greene, T. W, "Protective Groups in Organic Synthesis,"
John Wiley and Sons, New York, New York, pp. 206-207
(1981).
Schneider et al., J. Nucl Med., vol. 25, pp. 223-229 (1984),
"N,N'-bis-S-Benoylmercaptoacetamido ethylenediamine
and propylenediamine ligands as renal function imaging
agents. I. Alternate synthetic methods".
Costello et al., /. Nucl. Med., vol. 24, pp. 353-355, 1983,
"The investigation of radiopharmaceutical components by
fast atom bombardment mass spectrometry=The identifica-
tion of Tc-HIDA and the epimers of Tc-Co2DADS".
Liang et al., J. Nucl. Med., vol. 27, No. 6, p. 1051, Abstract
No. 720, (Jun. 1986), "Serum-stability and non-specific
binding of technetium-99m labeled diaminodithiol for pro-
tein labeling".
Paganelli et al., "Intraperitoneal Radio-Localization of
Tumors Pre-targeted by Biotinylated Monoclonal Antibod-
ies," Int. J. Cancer, vol. 45, pp. 1184-1189, 1990.
Paganelli et al., "Monoclonal antibody pretargeting tech-
niques for tumour localization: the avidin-biotin system,"
Nucl. Med. Communications, vol. 12, pp. 211-234, 1991.
Goodwin/Hnatowich, Letter to the Editor/Reply, J. Nucl.
Med., vol. 32, No. 4 pp. 750-751, 1991.
Green, "The use of [14C]Biotin for Kinetic Studies and for
Assay", Biochem. J., vol. 89, p. 585, 1963.
Kalofonos et al., "Imaging of Tumor in Patients with
Indium-IH-Labeled Biotin and Streptavidin-Conjungated
Antibodies: Preliminary Communication,',' J. Nucl. Med.,
vol. 31, No. 11, pp. 1791-1796, 1990.
Hnatowich et al., "Investigations of Avidin and Biotin for
Imaging Applications," J. Nucl. Med., vol. 28, No. 8, pp.
1294-1302, 1987.
Rosebrough, Abstract No. 235, J. Nucl. Med., p. 880, 1992,
"Plasma stability and Pharmacokinetics of Radio-labeled
Deferozamine-Biotin Derivatives".
Virzi et al., Abstract No. 403, /. Nucl. Med., p. 920, 1992,
"The preparation and Evaluation of 12 Biotin Derivatives
labeled with Tc-99m".
Rosario et al., Abstract No. 356, J. Nucl. Med., vol. 32, No. 5, p. 993, 1991, "Bolton-Hunter and Biotin derivatized polylysine: A new multi-valent peptide reagent for in vivo pre-targeting with streptavidin conjugates".
Primary Examiner—Floyd D. Higel
Attorney, Agent, or Firm—Burns, Doane, Swecker &
Mathis, LLP
[57] ABSTRACT
Protein, ligand and anti-ligand conjugated chelated metal radionuclides are provided for use in vivo. Intermediates are provided for preparing the compositions efficiently.
11 Claims, 13 Drawing Sheets
|
